PRA Health Sciences, Inc. (NASDAQ:PRAH) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $78.20.

A number of equities research analysts have commented on the stock. Bank of America Corporation assumed coverage on shares of PRA Health Sciences in a report on Monday, June 26th. They issued a “buy” rating and a $89.00 price target for the company. Citigroup Inc. reaffirmed a “buy” rating and issued a $90.00 price objective (up from $73.00) on shares of PRA Health Sciences in a research note on Wednesday, June 28th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $76.00 price objective (up from $69.00) on shares of PRA Health Sciences in a research note on Tuesday, June 6th. Finally, Jefferies Group LLC set a $73.00 price objective on shares of PRA Health Sciences and gave the company a “buy” rating in a research note on Thursday, June 1st.

PRA Health Sciences (PRAH) traded up 0.48% on Tuesday, hitting $75.41. 135,467 shares of the stock were exchanged. PRA Health Sciences has a 1-year low of $41.01 and a 1-year high of $79.98. The company has a market capitalization of $4.71 billion, a PE ratio of 45.05 and a beta of 0.48. The company has a 50-day moving average price of $72.62 and a 200 day moving average price of $63.15.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Tuesday, April 25th. The medical research company reported $0.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.02. The business had revenue of $427.08 million during the quarter, compared to the consensus estimate of $426.81 million. PRA Health Sciences had a net margin of 5.85% and a return on equity of 21.87%. The firm’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.55 EPS. Analysts anticipate that PRA Health Sciences will post $3.15 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/11/pra-health-sciences-inc-prah-receives-consensus-rating-of-buy-from-brokerages.html.

In other news, VP Linda Baddour sold 196,393 shares of the company’s stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $63.59, for a total value of $12,488,630.87. Following the sale, the vice president now directly owns 124,472 shares of the company’s stock, valued at approximately $7,915,174.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is owned by corporate insiders.

Several institutional investors have recently modified their holdings of the company. First Bank & Trust boosted its position in shares of PRA Health Sciences by 1.7% in the first quarter. First Bank & Trust now owns 3,159 shares of the medical research company’s stock valued at $206,000 after buying an additional 54 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in PRA Health Sciences by 0.6% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 21,752 shares of the medical research company’s stock worth $1,199,000 after buying an additional 130 shares during the last quarter. Forward Management LLC boosted its stake in PRA Health Sciences by 5.0% in the first quarter. Forward Management LLC now owns 4,762 shares of the medical research company’s stock worth $310,000 after buying an additional 226 shares during the last quarter. 1st Global Advisors Inc. boosted its stake in PRA Health Sciences by 2.2% in the first quarter. 1st Global Advisors Inc. now owns 11,265 shares of the medical research company’s stock worth $735,000 after buying an additional 238 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in PRA Health Sciences by 7.1% in the first quarter. Legal & General Group Plc now owns 9,943 shares of the medical research company’s stock worth $649,000 after buying an additional 663 shares during the last quarter.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.